ADVENTRX to Present Thiovir Preclinical Data at the 20th International Conference on Antiviral Research
February 12 2007 - 6:30AM
PR Newswire (US)
SAN DIEGO, Feb. 12 /PRNewswire-FirstCall/ -- ADVENTRX
Pharmaceuticals, Inc. (AMEX:ANX), a biopharmaceutical company
developing anticancer and antiviral therapies, announced today that
data from preclinical studies of Thiovir(TM), a drug candidate in a
new class of reverse transcriptase inhibitors (RTIs), will be
presented at the 20th International Conference on Antiviral
Research (ICAR) in Palm Springs, April 30 - May 4 2007. The
abstract entitled "Combinations of Thiovir and neuraminidase
inhibitors exert synergistic antiviral activity on human, equine
and avian influenza in vitro" will be presented on May 2, 2007.
"The ICAR data in avian influenza coupled with previously reported
preclinical results are convincing evidence for the importance of
further development and evaluation of this broad spectrum antiviral
and novel reverse transcriptase inhibitor in the treatment of
influenza viruses," said Evan M. Levine, Chief Executive Officer of
ADVENTRX. "We currently plan to initiate a Phase I/II clinical
trial of Thiovir in HIV positive patients later this year." About
Thiovir (ANX-201) Thiovir (ANX-201) is a pyrophosphate analogue, a
new class of reverse transcriptase inhibitor (RTI) designed for
oral delivery as a component of AZT- based highly active
antiretroviral therapy (HAART). Thiovir is an analogue of foscarnet
that delivers both the active drug TPFA (thiophosphonoformate) and
the active metabolite PFA (foscarnet) in an oral formulation.
Thiovir is intended to deliver the benefits of the drug foscarnet,
including broad spectrum antiviral activity, with the added benefit
of improved cell permeability. ADVENTRX currently plans to initiate
a Phase I/II clinical trial of Thiovir in HIV positive patients in
2007. About ADVENTRX Pharmaceuticals ADVENTRX Pharmaceuticals is a
biopharmaceutical research and development company focused on
commercializing anticancer and antiviral therapies that improve the
performance and safety of existing treatments by addressing
significant problems such as drug metabolism, toxicity,
bioavailability and resistance. The Company's lead product
candidate, CoFactor (ANX-510), currently is being tested in a
pivotal Phase III study for metastatic colorectal cancer in the US.
More information can be found on the Company's web site at
http://www.adventrx.com/. Forward Looking Statement ADVENTRX
cautions you that statements included in this press release that
are not a description of historical facts are forward-looking
statements that involve risks, uncertainties, assumptions and other
factors that, if they do not materialize or prove to be accurate,
could cause ADVENTRX's results to differ materially from historical
results or those expressed or implied by such forward-looking
statements. Such forward-looking statements are made based on
management's current expectations and beliefs and should not be
regarded as a statement or representation by ADVENTRX that any of
its plans, including its anticipated milestones, will be achieved
on time or at all. The potential risks and uncertainties that could
cause actual results to differ materially include, but are not
limited to: the risk that ADVENTRX will be unable to raise
sufficient capital to fund the projects necessary to meet its
anticipated or stated goals and milestones, including funding the
continued development of Thiovir(TM); the potential to attract a
strategic partner for Thiovir(TM) or any of ADVENTRX's other
product candidates and the terms of any related transaction; the
ability to timely enroll subjects in ADVENTRX's current and
anticipated clinical trials, including the currently planned Phase
I/II clinical trial of Thiovir(TM); the results of planned clinical
trials for Thiovir(TM) or ADVENTRX's other product candidates; the
potential for Thiovir(TM) and ADVENTRX's other product candidates
to receive regulatory approval for one or more indications on a
timely basis or at all, and the uncertain process of seeking
regulatory approval; other difficulties or delays in developing,
testing, manufacturing and marketing of and obtaining regulatory
approval for Thiovir(TM) or ADVENTRX's other product candidates;
the market potential for reverse transcriptase inhibitors and other
target markets, and ADVENTRX's ability to compete in those markets;
unexpected adverse side effects or inadequate therapeutic efficacy
of Thiovir(TM) or ADVENTRX's other products candidates that could
delay or prevent regulatory approval or commercialization, or that
could result in recalls or product liability claims; the risk that
preclinical and clinical results are not indicative of the success
of subsequent clinical trials and that products will not perform as
preclinical and clinical data suggests or as otherwise anticipated;
the potential for regulatory authorities to require additional
preclinical work or other clinical requirements to support
regulatory filings; the scope and validity of patent protection for
Thiovir(TM) and ADVENTRX's other product candidates; and other
risks and uncertainties more fully described in ADVENTRX's press
releases and periodic filings with the Securities and Exchange
Commission. ADVENTRX's public filings with the Securities and
Exchange Commission are available at http://www.sec.gov/. You are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date when made. All
forward-looking statements are qualified in their entirety by this
cautionary statement and ADVENTRX assumes no obligation to revise
or update any forward-looking statement, including as set forth in
this press release, to reflect events or circumstances arising
after the date on which it was made. DATASOURCE: ADVENTRX
Pharmaceuticals, Inc. CONTACT: Amy Martini, Media Contact for
WeissComm Partners, +1-212-301-7223; Ioana C. Hone, Investor
Contact for ADVENTRX Pharmaceuticals, +1-858-552-0866 Web site:
http://www.adventrx.com/ Company News On-Call:
http://www.prnewswire.com/gh/cnoc/comp/920134.html
Copyright
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jul 2023 to Jul 2024